Latest On Bristol-Myers Squibb Company PFD CONV 2 (BMYMP):
About Bristol-Myers Squibb Company PFD CONV 2 (BMYMP):
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection. Its products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in atrial fibrillation and the prevention and treatment of venous thromboembolic disorders; Orencia, a biological product that targets adult patients with active rheumatoid arthritis and prostate-specific antigen; and Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. The company's products also comprise Yervoy, a monoclonal antibody for the treatment of adults and pediatric patients with unresectable or metastatic melanoma; Empliciti, a human monoclonal antibody for the treatment of multiple myeloma; Baraclude, a potent and selective inhibitor of the hepatitis B virus; Sustiva, a non-nucleoside reverse transcriptase inhibitor for HIV and bulk efavirenz; Reyataz, a protease inhibitor for the treatment of HIV and combination therapy Evotaz; Daklinza, an oral small molecule NS5A replication complex inhibitor for the treatment of hepatitis C virus (HCV); and Sunvepra, an oral small molecule for the treatment of HCV. It sells products to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. Bristol-Myers Squibb Company has a research partnership with Sirenas; and a collaboration agreement with Nektar Therapeutics, Illumina, Inc., Janssen Pharmaceuticals, Inc., and Advantagene, Inc., as well as Tsinghua University. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
General
- Name Bristol-Myers Squibb Company PFD CONV 2
- Symbol BMYMP
- Type Common Stock
- Exchange PINK
- Currency USD
- Country USA
- SectorOther
- IndustryOther
- Full Time Employees 23,700
- Fiscal Year EndDecember
Valuation
- Trailing PE 4755.56
Financials
- Most Recent Quarter 2020-12-31
- Revenue Per Share $0
- Quarterly Earnings Growth 0%
Highlights
- Market Capitalization 1.75 trillion
- PE Ratio 12.34
Share Statistics
- % Held by Insiders <1%
Technicals
- 52 Week High $1497.19
- 52 Week Low $779.44
- 50 Day Moving Average 1116.25
- 200 Day Moving Average 1115.1
Dividends
- Forward Annual Dividend Yield 0.12%
- Dividend Date 2021-06-01
- ExDividend Date N/A
- Dividend Per Share $1.59
- Dividend Yield 0%
Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) Dividend Calendar:
BMYMP's last dividend payment was made to shareholders on June 1, 2021.
Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
---|
Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
---|---|---|---|---|---|
2020-09-30 | 2020-12-31 | $10.54 billion | -$4.45 | $0.00 | |
2020-06-30 | 2020-09-30 | $10.13 billion | $0.82 | $0.00 | |
2020-03-31 | 2020-06-30 | $10.78 billion | -$0.04 | $0.00 | |
2019-12-31 | 2020-03-31 | $7.95 billion | -$0.34 | $0.00 | |
2019-09-30 | 2019-12-31 | $6.01 billion | -$0.55 | $0.00 | |
2019-06-30 | 2019-09-30 | $6.27 billion | $0.83 | $0.00 | |
2019-03-31 | 2019-06-30 | $5.92 billion | $0.87 | $0.00 | |
2018-12-31 | 2019-03-31 | $1.04 | $0.00 | ||
2018-09-30 | 2018-12-31 | $0.71 | $0.00 | ||
2018-06-30 | 2018-09-30 | $1.16 | $0.00 | ||
2018-03-31 | 2018-06-30 | $5.19 billion | $0.23 | $0.00 | |
2017-12-31 | 2018-03-31 | $5.45 billion | $0.91 | $0.00 | |
2017-09-30 | 2017-12-31 | $5.25 billion | -$1.43 | $0.00 | |
2017-06-30 | 2017-09-30 | $5.14 billion | $0.51 | $0.00 | |
2017-03-31 | 2017-06-30 | $4.93 billion | $0.56 | $0.00 | |
2016-12-31 | 2017-03-31 | $0.94 | $0.00 | ||
2016-09-30 | 2016-12-31 | $0.53 | $0.00 | ||
2016-06-30 | 2016-09-30 | $0.72 | $0.00 | ||
2016-03-31 | 2016-06-30 | $0.69 | $0.00 | ||
2015-12-31 | 2016-03-31 | $0.71 | $0.00 | ||
2015-09-30 | 2015-12-31 | -$0.12 | $0.00 | ||
2015-06-30 | 2015-09-30 | $0.42 | $0.00 | ||
2015-03-31 | 2015-06-30 | -$0.08 | $0.00 | ||
2014-12-31 | 2015-03-31 | $0.71 | $0.00 | ||
2014-09-30 | 2014-12-31 | $0.01 | $0.00 | ||
2014-06-30 | 2014-09-30 | $0.43 | $0.00 | ||
2014-03-31 | 2014-06-30 | $0.20 | $0.00 | ||
2013-12-31 | 2014-03-31 | $0.56 | $0.00 | ||
2013-09-30 | 2013-12-31 | $0.43 | $0.00 | ||
2013-06-30 | 2013-09-30 | $0.42 | $0.00 | ||
2013-03-31 | 2013-06-30 | $0.32 | $0.00 | ||
2012-12-31 | 2013-03-31 | $0.37 | $0.00 | ||
2012-09-30 | 2012-12-31 | $0.56 | $0.00 | ||
2012-06-30 | 2012-09-30 | -$0.43 | $0.00 | ||
2012-03-31 | 2012-06-30 | $0.38 | $0.00 | ||
2011-12-31 | 2012-03-31 | $0.64 | $0.00 | ||
2011-09-30 | 2011-12-31 | $0.50 | $0.00 | ||
2011-06-30 | 2011-09-30 | $0.56 | $0.00 | ||
2011-03-31 | 2011-06-30 | $0.52 | $0.00 | ||
2010-12-31 | 2011-03-31 | $0.57 | $0.00 |
Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
---|---|---|---|---|---|
Research Development | 3.75 billion | 2.5 billion | 2.52 billion | 2.37 billion | 2.09 billion |
Income Before Tax | -10.45 billion | 2.26 billion | 1.63 billion | -304 million | -129 million |
Selling General Administrative | 2.72 billion | 1.71 billion | 1.63 billion | 1.61 billion | 1.73 billion |
Gross Profit | 8.16 billion | 8.04 billion | 7.43 billion | 7.12 billion | 5.51 billion |
Ebit | -7.57 billion | 5.26 billion | 4.54 billion | 2.54 billion | 1.39 billion |
Operating Income | -839 million | 1.34 billion | 891 million | 783 million | 557 million |
Income Tax Expense | N/A | N/A | N/A | N/A | N/A |
Total Revenue | 11.07 billion | 10.54 billion | 10.13 billion | 10.78 billion | 7.95 billion |
Cost of Revenue | 2.91 billion | 2.5 billion | 2.7 billion | 3.66 billion | 2.43 billion |
Total Other Income Expense Net | -9.26 billion | 1.26 billion | 1.09 billion | -725 million | -407 million |
Net Income From Continuing Operations | -10.03 billion | 1.88 billion | -80 million | -766 million | -1.06 billion |
Net Income Applicable to Common Shares | N/A | N/A | N/A | N/A | N/A |
Cash Flow:
Date | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 | Jun 30 2019 | Mar 31 2019 |
---|---|---|---|---|---|
Investments | 653 million | -12.04 billion | 491 million | 715 million | 1.06 billion |
Change to Liabilities | N/A | N/A | N/A | N/A | N/A |
Total Cash Flow from Investing Activities | N/A | N/A | N/A | N/A | N/A |
Net Borrowings | N/A | N/A | N/A | N/A | N/A |
Total Cash Flow from Financial Activities | -1.05 billion | -7.68 billion | -941 million | 18.27 billion | -2.03 billion |
Change to Operating Activities | N/A | N/A | N/A | N/A | N/A |
Change in Cash | 3.43 billion | -17.67 billion | 2.09 billion | 21.07 billion | 424 million |
Total Cash from Operating Activities | 3.89 billion | N/A | N/A | N/A | N/A |
Depreciation | 2.48 billion | 1.24 billion | 171 million | 169 million | 170 million |
Other Cash Flow from Investing Activities | N/A | N/A | N/A | N/A | N/A |
Change to Inventory | 1.45 billion | 470 million | -35 million | -7 million | 35 million |
Change to Account Receivables | N/A | N/A | N/A | N/A | N/A |
Other Cash Flow from Financing Activities | N/A | N/A | N/A | N/A | N/A |
Change to Net Income | N/A | N/A | N/A | N/A | N/A |
Capital Expenditures | 186 million | 251 million | 190 million | 191 million | 204 million |
Balance Sheet:
Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
---|---|---|---|---|---|
Total Liabailities | N/A | 75.31 billion | 78.92 billion | 79.31 billion | 78.25 billion |
Total Stockholder Equity | N/A | 50.16 billion | 49.09 billion | 49.91 billion | 51.6 billion |
Other Current Liabilities | N/A | 11.12 billion | 11 billion | 8.06 billion | 7.89 billion |
Total Assets | N/A | 125.54 billion | 128.08 billion | 129.29 billion | 129.94 billion |
Common Stock | N/A | N/A | N/A | N/A | N/A |
Other Current Assets | N/A | 1.35 billion | 1.38 billion | 2.41 billion | 1.98 billion |
Retained Earnings | N/A | 32.41 billion | 31.57 billion | 32.67 billion | 34.47 billion |
Other Liabilities | N/A | N/A | N/A | N/A | N/A |
Other Assets | N/A | N/A | N/A | N/A | N/A |
Cash | 14.55 billion | 19.44 billion | 19.93 billion | 15.82 billion | 12.35 billion |
Total Current Liabilities | N/A | 20.46 billion | 23.42 billion | 19.23 billion | 18.3 billion |
Other Stockholder Equity | N/A | N/A | N/A | N/A | N/A |
Property, Plant & Equipment | N/A | N/A | N/A | N/A | N/A |
Total Current Assets | N/A | 34.28 billion | 34.34 billion | 31.85 billion | 29.35 billion |
Long Term Investments | N/A | 4.66 billion | 4.41 billion | 651 million | 767 million |
Net Tangible Assets | N/A | N/A | N/A | N/A | N/A |
Short Term Investments | 1.29 billion | 1.85 billion | 1.86 billion | 2.51 billion | 3.05 billion |
Long Term Debt | N/A | 41.36 billion | 41.85 billion | 42.84 billion | 43.39 billion |
Inventory | N/A | 1.95 billion | 2.38 billion | 2.84 billion | 4.29 billion |
Accounts Payable | N/A | 2.44 billion | 2.85 billion | 3.07 billion | 2.45 billion |
Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) Chart:
Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) News:
Below you will find a list of latest news for Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
---|
Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
Date | Form Type | Form Name | Link |
---|